

Company Overview

- NurExone is developing **breakthrough exosome-based therapies** to regenerate nerves and recover function in debilitating conditions. The therapies leverage **the natural healing power** of exosomes, which are derived from human stem cells and loaded with **therapeutic molecules** using our proprietary technology.
- Our lead product therapy, Exo-PTEN, is being developed for **multiple high-impact neuronal indications**, including optic nerve degeneration in glaucoma and other eye diseases, acute spinal cord injury, and facial nerve paralysis.
- NurExone is also moving into supply of exosomes for **regenerative aesthetics** and Exosomes based Non-Drug Applications, a field where exosomes' **healing** and **regenerative** properties are expected to drive a **huge market opportunity**. This strategy allows the company to generate revenue from both the medical and aesthetic sides of the growing exosome market¹.

A Multi-Billion Dollar Opportunity in Science-Backed Aesthetics

- Exosomes are emerging as a **new frontier** in regenerative **beauty** and **wellness** through science-driven, minimally invasive treatments. Harnessing their powerful cargo of growth factors, proteins, and microRNAs, exosomes are being explored for transformative applications in **skin rejuvenation** and **anti-aging, wound healing, diabetic ulcers, and hair regeneration**.
- The market for **exosome-based regenerative aesthetics** is experiencing **explosive growth**, driven by rising demand for premium procedures that deliver visible results. **This sector is projected to surge past \$1.6 billion by 2034**, driven by growing demand for premium procedures priced between \$500 and \$2,500 per session, with most clients undergoing multiple treatments each year.
- Media outlets like **Allure** and **Harper's Bazaar** and major conferences such as the **Aesthetic & Anti-Aging Medicine World Congress (AMWC)** and the **International Master Course on Aging Science (IMCAS)** are spotlighting exosomes as a **transformative innovation** in aesthetic medicine.

Exo-Top Inc. - US Based Exosome Production from a Master Cell Bank


The company recently acquired a proprietary Master Cell Bank (MCB) of Mesenchymal Stem Cells (MSCs) that is expected to **produce** consistent, high-quality exosomes with high biological potency.

NurExone is establishing **Exo-Top Inc.**, a wholly owned U.S.-based subsidiary, to develop production capabilities using this **strategic asset**. U.S. based manufacture will provide **proximity to key markets** and the ability to meet demand quickly while ensuring regulatory confidence among U.S. customers.

The Exo-Top Inc. produced exosomes will be both for NurExone's **therapeutic pipeline**, where they serve as the delivery vehicle for ExoPTEN, targeting nerve injury, and for the rapidly expanding **exosome regenerative market**.


This **dual-use capability** will position Exo-Top Inc. above commodity suppliers, offering investors **near-term revenue** from high-demand aesthetic and exosome-based non-drug application markets and significant **long-term value** as the foundation for next-generation therapeutics.

Commercial sales are targeted to begin on **2026** through a robust distribution network.



Market Potential by Region²

Exosome-Based Aesthetic and Non-Drug Applications



Market size and CAGR estimates: Grand View Research, Exosome Research Report, 2024.

Company Status & Vision

- NurExone Biologic is a publicly traded company with listings on the TSXV (NRX) in Canada, quoted in the OTCQB (NRXBF) in the US and Germany (J90F). To date, the company has successfully raised approximately **US\$17 million**, supporting its ambitious growth and product development roadmap.
- Exo-Top's strategic direction is guided by NurExone's leadership and **Mr. Jacob Licht**, CEO of Exo-Top Inc. Mr. Licht, who has led transactions totaling \$1 billion across mergers and acquisitions, licensing, and asset sales in the pharmaceutical industry, will strengthen the commercial strategy and positioning.
- With Exo-Top Inc., NurExone is building the **foundation of exosome medicine** — ensuring the **high-quality, clinical-grade supply** of exosomes needed for its own groundbreaking nerve damage therapies and for the broader industry.

NurExone Biologic:

Where Nature Ends, NurExone Begins

For more information, please contact:

jacobl@nurexone.com

TSXV: NRX | OTCQB: NRXBF

Disclaimer

The matters discussed in this document are forward-looking statements that involve a number of risks and uncertainties.

The actual future results of the company could differ significantly from those statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

This document does not constitute an offer to sell or a solicitation of offers to buy any securities of the company or any entity.

For references, please visit - <https://www.sedarplus.ca/landingpage/>, then at the select profile, please write NurExone.

References

- [NurExone company profile and TSXV listing:](#)
- [Market size and CAGR estimates: Grand View Research, Exosome Research Report, 2024.](#)
- [Regulatory Overview \(Utah\) SB199 and SB275](#)
- [Regulatory Overview \(Florida\) SB1617 and SB1768](#)

New Legal Frameworks Accelerating Commercial Use of Exosomes in the US^{3,4}

- Recently enacted laws such as Utah SB199 and SB275 (2024) and Florida SB167 and SB1768 (2025) in the U.S. are opening **new avenues for exosome-based therapies** for certain conditions under patient disclosure and regulatory standards. Numerous exosome aesthetic clinics have already opened in Utah.
- These changes are being driven by physicians, clinic networks, advocacy groups, and lawmakers responding to patient demand for **regenerative** solutions like exosomes.
- This momentum is opening a **massive market opportunity** that NurExone will be ideally positioned to capture with its clinical-grade, GMP-compliant exosome production.

Competitive Landscape

Company	Business Focus	Therapeutic Applications	US GMP Production	Cell Source Quality
Exo-Top Inc (U.S.)	Naïve exosome production for therapeutic and other applications	✓ Yes – integrated into NurExone's therapeutic pipeline	✓ Yes – production will take place in the US under GMP conditions.	✓ GMP, fully characterized, FDA-approved cells from single donor of Human Bone Marrow Mesenchymal Stem Cells
Kimera Labs (U.S.)	Cosmetic and wellness exosomes	✗ No therapeutic products	⚠ US production but non-therapeutic grade	⚠ No public details on GMP or FDA-approved cells
ExoCoBio (S. Korea)	Cosmetic and wellness exosomes	✗ No therapeutic products	✗ Outside US	⚠ No public details on cell source and GMP or FDA approved cells
Regenestem (LATAM)	Aesthetic exosome treatments	✗ No therapeutic products	✗ Not US-based	✗ Not GMP therapeutic-grade
Novastem (LATAM)	Aesthetic exosome treatments	✗ No therapeutic products	✗ Not US-based	✗ Not GMP therapeutic-grade
Direct Biologics (U.S.)	Naive exosome therapeutics for own use; No known B2B supply	✓ Yes –clinical programs (ARDS, IBD)	✓ Yes – US production	⚠ No public details on GMP or FDA-approved cell

The Science Behind MSC-derived Exosomes

Mesenchymal stem cell (MSC)-derived exosomes are extracellular vesicles harvested from MSCs. Their nanoscale size enables **deep tissue penetration** and facilitates **targeted delivery of bioactive molecules**, suggesting regenerative, anti-aging, wound healing, and skin rejuvenation properties, enhanced collagen production, reducing wrinkles, and improved overall skin texture and longevity-related applications. MSC-derived exosomes are immunologically inert, non-toxic, and have shown promising safety profiles in numerous clinical studies. When produced under Good Manufacturing Practices (GMP), they can ensure a **standardized, highly characterized, and pure product**.